UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4116-15, Article 4116

2022

Volltextzugriff (PDF)

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

Breast cancer research : BCR, 2023-11, Vol.25 (1), p.138-138, Article 138

2023

Volltextzugriff (PDF)

Novel Methods and Tracers for Breast Cancer Imaging

Seminars in nuclear medicine, 2013-07, Vol.43 (4), p.324-329

2013

Volltextzugriff (PDF)

Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer

Journal of clinical oncology, 2006-06, Vol.24 (18), p.2793-2799

2006

Volltextzugriff (PDF)

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Breast cancer research : BCR, 2021-08, Vol.23 (1), p.1-11, Article 88

2021

Volltextzugriff (PDF)

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Clinical cancer research, 2011-04, Vol.17 (8), p.2400-2409

2011

Volltextzugriff (PDF)

Clinical Potential of Estrogen and Progesterone Receptor Imaging

PET clinics, 2018-07, Vol.13 (3), p.415-422

2018

Volltextzugriff (PDF)

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4449-4457

2008

Volltextzugriff (PDF)

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

EJNMMI research, 2024-03, Vol.14 (1), p.32-11, Article 32

2024

Volltextzugriff (PDF)

Test–Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network

The Journal of nuclear medicine (1978), 2019-05, Vol.60 (5), p.608-614

2019

Volltextzugriff (PDF)

Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?

Clinical cancer research, 2023-06, Vol.29 (11), p.2015-2016

2023

Volltextzugriff (PDF)

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Clinical cancer research, 2010-05, Vol.16 (10), p.2803-2810

2010

Volltextzugriff (PDF)

Whole‐Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α‐18F‐Fluoro‐17β‐Estradiol Positron Emission Tomography: Meta‐Analysis and Recommendations for Integration into Clinical Applications

The oncologist (Dayton, Ohio), 2020-10, Vol.25 (10), p.835-844

2020

Volltextzugriff (PDF)

Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Breast cancer research and treatment, 2007-09, Vol.105 (1), p.87-94

2007

Volltextzugriff (PDF)

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Breast cancer research and treatment, 2014-10, Vol.147 (3), p.609-616

2014

Volltextzugriff (PDF)

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer

Clinical cancer research, 2017-01, Vol.23 (2), p.407-415

2017

Volltextzugriff (PDF)

Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer

Cancer epidemiology, biomarkers & prevention, 2024-02, Vol.33 (2), p.288-297

2024

Volltextzugriff (PDF)

Fluorine-18-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies—AJR Expert Panel Narrative Review

American journal of roentgenology (1976), 2023-12

2023

Volltextzugriff (PDF)

Quantitative Imaging in Cancer Clinical Trials

Clinical cancer research, 2016-01, Vol.22 (2), p.284-290

2016

Volltextzugriff (PDF)

Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer

Journal of Nuclear Medicine, 2016-02, Vol.57 Suppl 1 (Supplement 1), p.75S-80S

2016

Volltextzugriff (PDF)

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Clinical cancer research, 2016-06, Vol.22 (12), p.2855-2864

2016

Volltextzugriff (PDF)

Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer

Journal of Nuclear Medicine, 2017-04, Vol.58 (4), p.560-562

2017

Volltextzugriff (PDF)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Breast cancer research and treatment, 2023-01, Vol.197 (2), p.319-331

2023

Volltextzugriff (PDF)

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3484-3492

2019

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Englisch
(182)

Erscheinungsjahr

n.n

Thema

Humans
(71)
Science & Technology
(71)
Life Sciences & Biomedicine
(64)
Female
(48)
Oncology
(39)
Breast Cancer
(38)
Middle Aged
(34)
Adult
(31)
Aged
(30)
Breast Neoplasms - Diagnostic Imaging
(25)
Breast Neoplasms - Drug Therapy
(24)
Radiology, Nuclear Medicine & Medical Imaging
(22)
Breast Neoplasms - Pathology
(21)
Tumors
(20)
Positron-Emission Tomography
(19)
Breast Neoplasms - Metabolism
(17)
Biological And Medical Sciences
(13)
Endocrine Therapy
(13)
Medical Sciences
(13)
Patients
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

Novel Methods and Tracers for Breast Cancer Imaging

Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Clinical Potential of Estrogen and Progesterone Receptor Imaging

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

Test–Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network

Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Whole‐Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α‐18F‐Fluoro‐17β‐Estradiol Positron Emission Tomography: Meta‐Analysis and Recommendations for Integration into Clinical Applications

Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer

Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer

Fluorine-18-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies—AJR Expert Panel Narrative Review

Quantitative Imaging in Cancer Clinical Trials

Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

Suchergebnisse filtern